Journal of Experimental & Clinical Cancer Research 2024

6 papers
The 2024 edition of the Journal of Experimental & Clinical Cancer Research emphasized the intersection of molecular signaling, epitranscriptomics, and the tumor microenvironment. Research themes focused on mapping oncogenic axes and identifying pharmacological gaps, with specific attention to selective translation and the active translatome. Studies investigated METTL1-mediated tRNA m7G methylation in breast cancer and the role of FBW7/GSK3β in degrading IGF2BP2 to mitigate radioresistance in lung cancer. Additional work explored metabolic-epigenetic coupling through histone modifications and the therapeutic induction of G2/M arrest and mitotic catastrophe. The journal also featured advancements in diagnostic and immunological research, including transcriptomics-based liquid biopsy panels for gastric cancer and single-cell RNA sequencing of the oral squamous cell carcinoma microenvironment. Investigations into regulatory B cells in bladder cancer and lactate-induced signaling pathways in gliomas highlighted trends in understanding immunotherapeutic sensitivity. Prolific contributors such as Chang Wang, Jing He, and Mingxia Zhou addressed the upstream triggers of molecular brake failure and targeted protein turnover via E3 ligases, reflecting a broader effort to overcome therapeutic resistance and improve the non-invasive identification of micrometastasis.

Top Research Directions

The 23 research directions with Journal of Experimental & Clinical Cancer Research 2024 papers, ranked by paper count, next to 2023. Share is the fraction of the edition’s papers in the direction.

#Direction20242023Share 2024Share 20232023 rank
1Multicellular Ecosystems and Ecotypes in the Tumor Microenvironment3050.0%0.0%—
2Translating Genetic Target Validation into Small Molecule Inhibitors2033.3%0.0%—
3Codon Biased Translation and Ribosome Specialization1116.7%16.7%2
4Deorphanizing E3 Ubiquitin Ligases and Their Substrates1016.7%0.0%—
5Epitranscriptomic Regulation of Tumor Growth and Immune Evasion1116.7%16.7%6
6Identifying Molecular Vulnerabilities for Tumor Growth Suppression1016.7%0.0%—
7Mapping Immune Landscapes with Multi-Parameter Flow Cytometry1016.7%0.0%—
8Mechanisms and Reversal Strategies of Tumor Radioresistance1016.7%0.0%—
9Mechanisms of Pro-Tumor Macrophage Polarization1116.7%16.7%8
10Multidimensional Biomarkers for Predicting Cancer Immunotherapy Response1016.7%0.0%—
11Multimodal Integration for Clinical Risk Stratification1016.7%0.0%—
12Overcoming Cell Line Specificity in Computational Oncology1016.7%0.0%—
13Overcoming the Immunosuppressive Tumor Microenvironment1116.7%16.7%11
14Predicting Occult Metastasis with Radiomics and Machine Learning1016.7%0.0%—
15Quantifying Cellular Behavior Through In Vitro Functional Assays1016.7%0.0%—
16Quantifying Protein Synthesis with Ribosome Profiling1016.7%0.0%—
17Reprogramming the Epigenome Through Cellular Metabolic Intermediates1116.7%16.7%12
18Resolving Cellular Heterogeneity via Single Cell Transcriptomics1016.7%0.0%—
19Substrate Recognition and Wiring in Targeted Proteasomal Degradation1016.7%0.0%—
20Targeting Cell Cycle Checkpoints for Cancer Therapy1016.7%0.0%—
21The Context Dependent Duality of Cancer Signaling1016.7%0.0%—
22Transcriptomic Signatures for Cancer Risk Stratification1016.7%0.0%—
23Upstream Triggers of Regulatory Gene Silencing1016.7%0.0%—

Download all directions as CSV

Institutions

Institutions credited by Journal of Experimental & Clinical Cancer Research 2024 papers: a paper credits every institution named in its affiliations, once. 5 institutions share 5 credited papers.

#InstitutionPapersShare20232023 rank
1Center for Excellence in Brain Science and Intelligence Technology 120.0%0—
2China Medical University 120.0%0—
3Hebei Medical University 120.0%0—
4Huazhong University of Science and Technology 120.0%13
5Zhengzhou University 120.0%17

Download all institutions as CSV

About this data

Papers. Journal of Experimental & Clinical Cancer Research 2024 lists 6 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2023 use shares, since the edition went from 6 to 6 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 5 of 6 papers (83.3%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Experimental & Clinical Cancer Research 2024”, https://lacuna.tiptreesystems.com/venue/journal-of-experimental-clinical-cancer-research/2024.

Impactful Papers

Papers from Journal of Experimental & Clinical Cancer Research 2024 that shaped research clusters.

Influential

Papers

Title
Analysis of the effect of CCR7 on the microenvironment of mouse oral squamous cell carcinoma by single-cell RNA sequencing technology
FBW7/GSK3β mediated degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback loop and radioresistance in lung cancer
GPR65 sensing tumor-derived lactate induces HMGB1 release from TAM via the cAMP/PKA/CREB pathway to promote glioma progression
Investigating the impact of regulatory B cells and regulatory B cell-related genes on bladder cancer progression and immunotherapeutic sensitivity
METTL1-mediated tRNA m7G methylation and translational dysfunction restricts breast cancer tumorigenesis by fueling cell cycle blockade
Transcriptomics-based liquid biopsy panel for early non-invasive identification of peritoneal recurrence and micrometastasis in locally advanced gastric cancer